Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. August 2022 08:00 ET | Quelle: eTheRNA Immunotherapies NV

mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA

Financing round led by Novalis LifeSciences LLCBoth investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien to join the board of directorsStrategic focus includes customized lipid...
05. April 2022 07:00 ET | Quelle: eTheRNA Immunotherapies NV

eTheRNA Announces Relocation and Expansion of R&D Facility

GENT, Belgium, April 05, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is...
28. März 2022 07:00 ET | Quelle: eTheRNA Immunotherapies NV

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

NIEL, Belgium, March 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid...
28. Februar 2022 07:00 ET | Quelle: eTheRNA Immunotherapies NV

eTheRNA Immunotherapies to Host Key Opinion Leader Webinar on mRNA-Lipid Nanoparticles for Cancer Immunotherapy

NIEL, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today...